TrialPath
Recruiting

A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder

NCT07772531 · Bristol-Myers Squibb
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of BMS-986511 in Two Sequential Parts in Participants With Major Depressive Disorder
About this study
A Study to Evaluate BMS-986511 in Adults with Major Depressive Disorder
Eligibility criteria
Inclusion Criteria: * Participants must meet the MDD diagnosis per DSM-5 criteria confirmed by structured interview. * Participant must have current moderate to severe MDE confirmed by clinical assessment and validated scale. * Participant must have current MDE duration \>12 weeks at screening. * Outpatient participants able to comply with study procedures. * Participant require medication washout completed before baseline. * Participant must have BMI within protocol range. * Participants must meet reproductive safety requirements. Exclusion Criteria: * Participants must not have other primary psychiatric disorders or a history of treatment-resistant depression during the current episode. * Participants must not have recent history of active suicidal ideation or attempt within the past year. * Participants must not have prior lifetime treatment with electroconvulsive therapy, ketamine/esketamine, deep brain stimulation, or transcranial magnetic stimulation. * Participants must not have recent history of alcohol/substance abuse or use of cannabis. * Participants must not have significant ECG abnormalities, or poorly controlled diabetes. * Other protocol defined inclusion/exclusion criteria apply.
Study design
Enrollment target: 200 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-10-30
Estimated completion: 2028-11-06
Last updated: 2026-11-18
Interventions
Drug: BMS-986511Drug: Placebo
Primary outcomes
  • • Mean change from baseline in Hamilton Depression Rating Scale -17 Item (HDRS-17) total score (Up to Day 57)
Sponsor
Bristol-Myers Squibb · industry
Contacts & investigators
ContactBMS Clinical Trials Contact Center www.BMSClinicalTrials.com · contact · Clinical.Trials@bms.com · 855-907-3286
ContactFirst line of the email MUST contain NCT # and Site #. · contact
InvestigatorBristol-Myers Squibb · study_director, Bristol-Myers Squibb
All locations (24)
Local Institution - 0144Not Yet Recruiting
Phoenix, Arizona, United States
Woodland International Research GroupRecruiting
Little Rock, Arkansas, United States
Woodland Research Northwest LLCRecruiting
Rogers, Arkansas, United States
Local Institution - 0046Not Yet Recruiting
Garden Grove, California, United States
Local Institution - 0042Not Yet Recruiting
Glendale, California, United States
Local Institution - 0071Not Yet Recruiting
Lemon Grove, California, United States
Local Institution - 0079Not Yet Recruiting
Oakland, California, United States
Local Institution - 0050Not Yet Recruiting
Upland, California, United States
Local Institution - 0007Not Yet Recruiting
Jacksonville, Florida, United States
Local Institution - 0024Not Yet Recruiting
Orlando, Florida, United States
CenExel CBHRecruiting
Atlanta, Georgia, United States
Local Institution - 0044Not Yet Recruiting
Gaithersburg, Maryland, United States
Local Institution - 0041Not Yet Recruiting
Cedarhurst, New York, United States
Local Institution - 0069Not Yet Recruiting
Mount Kisco, New York, United States
Local Institution - 0121Not Yet Recruiting
Staten Island, New York, United States
Local Institution - 0086Not Yet Recruiting
Columbus, Ohio, United States
Local Institution - 0027Not Yet Recruiting
Oklahoma City, Oklahoma, United States
Local Institution - 0003Not Yet Recruiting
Everett, Washington, United States
Local Institution - 0080Not Yet Recruiting
Prague, Czech Republic, Czechia
Local Institution - 0111Not Yet Recruiting
Prague, Praha 6, Czechia
Local Institution - 0032Not Yet Recruiting
Prague, Praha 8, Czechia
Local Institution - 0005Not Yet Recruiting
Kladno, Czechia
Local Institution - 0081Not Yet Recruiting
Klecany, Czechia
Local Institution - 0028Not Yet Recruiting
Pilsen, Czechia
A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder · TrialPath